HIV / AIDS

Today’s MMWR recommends twice-yearly subcutaneous lenacapavir for people ≥35 kg, citing PURPOSE-1/2 efficacy, a favorable safety profile with mostly mild to moderate injection-site reactions, and potential adherence benefits.

William Hanage, PhD, discusses viral evolution, transmission risk, and clinical implications for immunocompromised patients.

Up to 2 million people in low- and lower-middle-income countries may gain access to the long-acting PrEP option under a three-year, no-profit agreement.

David Margolis, MD discusses his team’s work at UNC looking at combination treatment that includes the cancer drug, vorinostat, and immunotherapy as a potential HIV cure.

WHO and HRP highlight new research on HIV communication, STI priorities, and inclusive strategies to strengthen sexual health worldwide.

UNC’s Sarah Rutstein, MD, PhD, discusses her research uncovering the inability of some people to receive HIV prevention medication in both the US and Africa and strategies to address it.

Joseph Eron, MD, provides insights on the unit's international reach as well as some of the important trials it has been involved in, notably the PURPOSE studies involving the landmark trials about lenacapavir for HIV prevention.

This review highlights how people living with HIV are living longer due to antiretroviral therapy but face unique age-related health challenges, including cardiovascular disease, metabolic syndrome, renal dysfunction, neurocognitive decline, immunosenescence, bone loss, and frailty, requiring tailored screening and management strategies.

A long-acting HIV-1 capsid inhibitor demonstrates over 99% efficacy, paving the way for expanded access to adults and adolescents across the EU and low-income countries.

Gilead Sciences has partnered with the Global Fund to supply up to 2 million doses of its long-acting HIV prevention drug, lenacapavir, to low and lower-middle income countries.

This investigational two-drug regimen for treatment of adults with virologically suppressed HIV was given a Prescription Drug User Fee Act (PDUFA) date of April 28, 2026.

Grace Kulik, PT, DPT, discusses key risk factors and the role of inflammation, ART, and screening in preserving mobility among aging individuals with HIV.

6–3 ruling preserves no-cost insurance coverage for preventive services such as HIV PrEP, contraceptives, and screenings.

Gilead’s Yeztugo, a long-acting HIV capsid inhibitor, shows 96 to 100% efficacy in phase 3 trials and aims to expand access worldwide through regulatory filings and support programs.

A coalition of over 100 US companies is supporting the federal initiative to end the HIV epidemic by 2030, but legal and funding threats now jeopardize this progress and the significant health and economic benefits it promises.

As the cohort of people living with HIV in the US ages, HIV care programs must rapidly adapt to the changing needs of older adults with HIV.

To meet ambitious targets for ending the HIV/AIDS epidemic, governments must unite in a global effort to improve access to CD4 testing.

Theratechnologies' new tesamorelin formulation provides a simplified, long-acting dosing regimen to effectively manage excess abdominal fat in adults with HIV-associated lipodystrophy.

A new analysis raises concerns over the stoppage of funding for this long-standing program, which could have major impacts on global public health for years to come.

The 15th anniversary of the Affordable Care Act is overshadowed by threats to HIV prevention efforts, including a looming Supreme Court case that could eliminate no-cost access to preexposure prophylaxis and other preventive services. Simultaneously, deep federal cuts and restructuring have destabilized critical public health infrastructure, jeopardizing decades of progress in the fight against HIV.

David Wohl, MD, explains the health risks of visceral fat and the role of treatments like Tesamorelin F8 in managing the condition.

David Wohl, MD, discusses the complexities of diagnosing and the importance of managing ectopic fat in HIV patients.

Studies presented included once-yearly lenacapavir formulations for PrEP, bictegravir outperforming darunavir in advanced HIV, Immunocore's IMC-M113V showing viral control and reservoir reduction, and more.